baltimore conference logo
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Endometrial Carcinoma Treatment Advances

Expert gynecologic oncologist Brian Slomovitz, MD, MS, FACOG, shares insight on novel therapeutic approaches to the management of endometrial cancer.

EP. 1: An Overview of Endometrial Cancer and Treatment Options

January 14th 2022

Expert perspectives on the endometrial cancer treatment landscape in light of approved therapies and drug classes.

EP. 2: Treating a Patient at Endometrial Cancer Relapse

January 14th 2022

Brian Slomovitz, MD, MS, FACOG, provides a brief review of endometrial cancer relapse and corresponding therapeutic approaches.

EP. 3: Combination of I/O and TKI Therapy in Endometrial Cancer

January 14th 2022

Insight on the combination of lenvatinib and pembrolizumab in endometrial cancer, investigated between the KEYNOTE-146 and KEYNOTE-775 trials.

EP. 4: Lenvatinib + Pembrolizumab in Endometrial Cancer: Practical Considerations

January 14th 2022

Practical perspectives on the optimal use of combination lenvatinib-pembrolizumab in endometrial cancer.

EP. 5: Novel Strategies Being Investigated in Endometrial Cancer

January 14th 2022

Brian Slomovitz, MD, MS, FACOG, shares excitement for novel and combination therapies being investigated in the endometrial cancer landscape.

EP. 6: Looking Toward the Future of Endometrial Cancer Management

January 14th 2022

Reflections on the future management of endometrial cancer and practical advice for practicing oncologists.